Celcuity (NASDAQ:CELC) Now Covered by Analysts at JPMorgan Chase & Co.

Key Points

• JPMorgan initiated coverage of Celcuity with an “overweight” rating and a $157 price target, implying approximately 90% upside from the reported share price.
• Analyst sentiment is broadly positive: 11 analysts rate the stock a Buy and one rates it a Sell, producing a “Moderate Buy” consensus and an average target of $154.75.
• Celcuity reported a quarterly loss of $1.44 per share, missing the $1.16 consensus estimate; institutional investors own 63.33% of the company.

Equities research analysts at JPMorgan Chase & Co. began coverage on shares of Celcuity (NASDAQ:CELC - Get Free Report) in a report issued on Thursday, Benzinga reports. The brokerage set an "overweight" rating and a $157.00 price target on the stock. JPMorgan Chase & Co.'s target price points to a potential upside of 90.12% from the stock's current price.

Several other research firms have also commented on CELC. HC Wainwright restated a "buy" rating and issued a $155.00 price objective on shares of Celcuity in a research note on Friday, August 14th. Wells Fargo & Company lowered their target price on shares of Celcuity from $183.00 to $166.00 and set an "overweight" rating on the stock in a research note on Wednesday, June 3rd. Stifel Nicolaus dropped their target price on shares of Celcuity from $175.00 to $150.00 and set a "buy" rating for the company in a report on Friday, August 14th. Citizens Jmp reiterated a "market outperform" rating and issued a $177.00 price target on shares of Celcuity in a research note on Monday, August 17th. Finally, Wall Street Zen cut Celcuity from a "sell" rating to a "strong sell" rating in a report on Saturday, August 15th. Eleven investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $154.75.

Celcuity Trading Down 0.1%

NASDAQ CELC opened at $82.58 on Thursday. The company has a quick ratio of 8.93, a current ratio of 8.93 and a debt-to-equity ratio of 6.04. The stock's 50 day moving average is $91.30 and its 200 day moving average is $105.67. The firm has a market capitalization of $4.04 billion, a PE ratio of -19.20 and a beta of 0.19. Celcuity has a twelve month low of $44.42 and a twelve month high of $151.02.

Celcuity (NASDAQ:CELC - Get Free Report) last released its earnings results on Thursday, August 13th. The company reported ($1.44) EPS for the quarter, missing analysts' consensus estimates of ($1.16) by ($0.28). Research analysts forecast that Celcuity will post -4.75 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Celcuity

Institutional investors have recently bought and sold shares of the business. California State Teachers Retirement System increased its position in shares of Celcuity by 91.2% during the 1st quarter. California State Teachers Retirement System now owns 25,580 shares of the company's stock valued at $2,920,000 after purchasing an additional 12,201 shares during the last quarter. Hsbc Holdings PLC bought a new position in Celcuity during the fourth quarter valued at $1,058,000. Geode Capital Management LLC increased its position in Celcuity by 8.4% during the fourth quarter. Geode Capital Management LLC now owns 830,684 shares of the company's stock valued at $82,872,000 after acquiring an additional 64,213 shares during the last quarter. E Fund Management Co. Ltd. purchased a new stake in shares of Celcuity in the second quarter valued at $4,802,000. Finally, TD Asset Management Inc raised its stake in shares of Celcuity by 34.0% in the fourth quarter. TD Asset Management Inc now owns 97,526 shares of the company's stock valued at $9,727,000 after acquiring an additional 24,730 shares during the period. Institutional investors own 63.33% of the company's stock.

About Celcuity

Celcuity, Inc is a biotechnology company focused on advancing personalized medicine through functional diagnostics. Its technology is designed to analyze living tumor cells obtained from patient tissue and identify abnormal signaling activity that may influence how a cancer responds to specific therapies.

The company's primary platform, CELsignia, uses proprietary assays to measure the activity of cellular signaling pathways in a patient's tumor cells. Celcuity develops these tests for use in oncology drug development, patient selection, and potentially as companion diagnostics to help identify patients who are most likely to benefit from targeted treatments.

Celcuity works with biopharmaceutical companies and research organizations to evaluate drug-response biomarkers and support precision oncology programs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.